Background About 20% of advanced non–small-cell lung cancer (NSCLC) cases harbor
somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor …

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and
erlotinib are known to have greater efficacy in EGFR mutation-positive non-small cell lung …

Purpose There is as yet no optimal treatment regimen for patients with epidermal growth
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …

Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with
advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor …

Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …

Large randomized phase III trials conducted in patients with non-small-cell lung cancer
(NSCLC) harboring activating mutations in EGFR have demonstrated that erlotinib or …

While assessing the efficacy of erlotinib in patients with epidermal growth factor receptor
(EGFR) wild‑type (WT) non‑small‑cell lung cancer (NSCLC), the sensitivity of the method …

Abstract Introduction The phase II JO25567 study compared the efficacy and safety of
erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal …

Purpose The epidermal growth factor receptor (EGFR) tyrosine kinase has been an
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …

Moreover, among the 104 patients who have obtained a disease control with gefitinib, 42
(40.4%) experienced a disease control (PR or SD) also from erlotinib treatment. Preclinical …